Trial Profile
Prospective Cohort Study to Assess the Safety and Efficacy of Replacing Tenofovir Disoproxil Fumarate by Tenofovir Alafenamide in HIV/HBV-coinfected Patients With Mild or Moderate Renal Dysfunction
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Jun 2023
Price :
$35
*
At a glance
- Drugs Cobicistat/elvitegravir/emtricitabine/tenofovir alafenamide (Primary) ; Emtricitabine/tenofovir alafenamide (Primary)
- Indications HIV infections
- Focus Pharmacodynamics
- 02 Jul 2020 Primary endpoint (Change in renal function) has been met, according results published in the JAIDS.
- 02 Jul 2020 Results published in the JAIDS
- 03 Mar 2020 Status changed from active, no longer recruiting to completed.